CSL SEQIRUS INVITES YOU TO A LIVE WEBCAST
FLUCELVAX AND REAL WORLD EVIDENCE:
A NEW CELL BASED INFLUENZA VACCINE
Join us as we introduce Flucelvax® Quad [Quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell cultures)], a new cell-based influenza vaccine. Cell-based technology is designed to be an exact match to the WHO-selected circulating strains.*1-5 We will discuss the difference between real world evidence and randomised clinical trials, and the place of real world data in influenza studies as well as understanding the risk factors and impact of influenza.
DATE:
THURSDAY NOV 2023
9
TO REGISTER:
TIME:
6:30 PM Online meeting room opens 30 minutes prior
www.seqirusevents.co.nz
OR Scan here
ACCESS CODE: FLUNZ23 PRESENTERS:
Prof. Dr. Tino Schwarz
Dr. Janine Paynter Public Health Epidemiologist, University of Auckland
Head of the Institute of Laboratory Medicine & Vaccination Centre, Klinikum Wuerzburg Mitte, Germany
Prof. Dr. Tino Schwarz is Head of the Institute of Laboratory Medicine and Vaccination Centre at the Klinikum Wuerzburg Mitte, Campus Juliusspital, Academic Teaching Hospital of the University of Wuerzburg in Germany. After gaining his medical degree at the University of Munich, he completed a year-long post in the army hospital in Munich, specialising in Internal Medicine, then took up a position at the Max von Pettenkofer Institute, University of Munich, where he worked in the field of medical virology and microbiology. He completed his PhD in the molecular biology, epidemiology, clinic and diagnostics of human parvovirus B19 infection then worked in the USA at the Center for Disease Control and Prevention. Returning to Germany he continued researching medical virology at the Max von Pettenkofer Institute with a focus on arboviruses. In 1996, he moved to the Klinikum Wuerzburg Mitte, Standort Juliusspital in Wuerzburg. Prof. Schwarz has been the principle investigator in several clinical vaccine trials with human papillomavirus (bivalent), influenza A/H5N1, influenza (QIV), tick-borne encephalitis, various adjuvants, zoster, pneumocooci, hepatitis B, TdaP-IPV, Influenza H1N1, meningococci B, meningococci ACWY, clostridium difficile, RSV and human papillomavirus (nonavalent, adjuvanted).
Janine is a public health epidemiologist at Conectus at the University of Auckland, New Zealand. Janine’s broader research experience includes research on non-communicable disease, tobacco control. This research informed policy change on tobacco displays. More recently her research projects have focussed on vaccine effectiveness and safety, including a study of the safety of pertussis immunisation in pregnancy. Janine’s strengths are in quantitative data analysis and data linkage. As part of the Monarch Collaboration, Janine is investigating vaccination coverage and rates of vaccine preventable disease amongst migrants using large, linkable New Zealand administrative datasets.
ENDORSED BY For 1.5 hours of professional development (CNA109)
This activity has been endorsed by the RNZCGP and has been approved for up to 1.5 CME credits for CPD purposes.